Objective. To evaluate the results of treating patients with stage III—IV prostate cancer without distant metastases using the developed scheme of polychemotherapy, 3D-conformal radiation therapy (RT), and long-term androgen deprivation.

Materials and methods. The randomized study included 91 patients with prostate cancer cT3a-4pN0-1M0 treated in 2006 to 2010 at N. N. Alexandrov National Cancer Centre of Belarus. Each patient of the main group additionally received polychemotherapy with «docetaxel + vinorelbine» on the background of radiotherapy, in the control group radiation and hormonal treatment was performed.

Results. The additional use of polychemotherapy with «docetaxel + vinorelbine» in patients with an unfavorable prognosis (pN1) allows a statistically significant increase of the 7-years cancer-specific survival by 23.3% in comparison with the course of HT+RT: the cancer-specific survival values in the main and control groups were 75.6±9.6 and 52.3±12.5, respectively (median — 88.6 months) (p=0.044).